NASDAQ:LUCD

Lucid Diagnostics - LUCD Stock Forecast, Price & News

$3.00

-0.04 (-1.32%)

(As of 08/18/2022 10:02 AM ET)

Add

Compare

Today's Range: $3.00
▼
$3.05
50-Day Range: $1.73
▼
$3.45
52-Week Range: $1.69
▼
$13.52

Volume: 1,800 shs
Average Volume: 116,658 shs
Market Capitalization: $113.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.54

Lucid Diagnostics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 251.4% Upside
$10.54 Price Target
Short Interest: Healthy
4.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.42) to ($1.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

891st out of 1,122 stocks

Surgical & Medical Instruments Industry

85th out of 112 stocks

3.5

Analyst's Opinion

Consensus Rating
Lucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.54, Lucid Diagnostics has a forecasted upside of 251.4% from its current price of $3.00.
Amount of Analyst Coverage
Lucid Diagnostics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.53% of the float of Lucid Diagnostics has been sold short.
Short Interest Ratio / Days to Cover
Lucid Diagnostics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Lucid Diagnostics has recently increased by 2.98%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Lucid Diagnostics does not currently pay a dividend.
Dividend Growth
Lucid Diagnostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUCD.

2.5

News and Social Media Coverage

News Sentiment
Lucid Diagnostics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Lucid Diagnostics this week, compared to 1 article on an average week.
Search Interest
3 people have searched for LUCD on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 8.84% of the stock of Lucid Diagnostics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Lucid Diagnostics are expected to decrease in the coming year, from ($1.42) to ($1.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lucid Diagnostics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lucid Diagnostics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lucid Diagnostics has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Lucid Diagnostics (NASDAQ:LUCD) Stock

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Ascendiant Capital Markets cut their price objective on Lucid Diagnostics to $13.00 in a research note on Thursday, June 9th. Needham & Company LLC cut their price objective on Lucid Diagnostics from $5.00 to $4.25 and set a "buy" rating for the company in a research note on Tuesday. Canaccord Genuity Group cut their price objective on Lucid Diagnostics from $12.00 to $8.00 in a research note on Thursday, May 12th. Finally, BTIG Research reiterated a "buy" rating and set a $5.00 price objective on shares of Lucid Diagnostics in a research note on Friday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $11.61.

Lucid Diagnostics Trading Down 7.3 %

NASDAQ:LUCD opened at $3.04 on Thursday. The stock's 50 day moving average is $2.57 and its 200 day moving average is $2.76. Lucid Diagnostics has a 12 month low of $1.69 and a 12 month high of $13.52. The stock has a market cap of $115.32 million and a PE ratio of -1.93.

Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

LUCD Stock News Headlines

August 16, 2022 | seekingalpha.com

Lucid Diagnostics Inc. (LUCD) CEO Lishan Aklog on Q2 2022 Results - Earnings Call Transcript

August 16, 2022 | finance.yahoo.com

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

August 15, 2022 | finance.yahoo.com

What Type Of Shareholders Make Up Lucid Diagnostics Inc.'s (NASDAQ:LUCD) Share Registry?

August 11, 2022 | finance.yahoo.com

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

August 4, 2022 | finance.yahoo.com

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies

August 2, 2022 | finance.yahoo.com

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements

August 1, 2022 | finance.yahoo.com

Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022

July 29, 2022 | americanbankingnews.com

Reviewing Lucid Diagnostics (NASDAQ:LUCD) & Penumbra (NYSE:PEN)

July 19, 2022 | apnews.com

PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America

July 18, 2022 | finance.yahoo.com

Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference

July 4, 2022 | finance.yahoo.com

Is Lucid Diagnostics (NASDAQ:LUCD) In A Good Position To Deliver On Growth Plans?

May 11, 2022 | seekingalpha.com

Lucid Diagnostics' (LUCD) CEO Lishan Aklog on Q1 2022 Results - Earnings Call Transcript

May 11, 2022 | finance.yahoo.com

Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results

May 9, 2022 | finance.yahoo.com

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans

April 4, 2022 | finance.yahoo.com

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination

March 30, 2022 | seekingalpha.com

Lucid Diagnostics Non-GAAP EPS of -$0.22, revenue of $0.3M

March 30, 2022 | msn.com

How Is The Market Feeling About Lucid Diagnostics Inc. - Common Stock?

March 30, 2022 | finance.yahoo.com

Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference

March 30, 2022 | benzinga.com

Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $7

March 29, 2022 | msn.com

Lucid Diagnostics to Have a Productive Year, Says Cantor Fitzgerald

March 29, 2022 | finance.yahoo.com

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

March 28, 2022 | finance.yahoo.com

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

March 24, 2022 | seekingalpha.com

PAVmed-Lucid esophageal precancer detection test in DOD funded study

March 24, 2022 | finance.yahoo.com

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study

March 23, 2022 | seekingalpha.com

Lucid Diagnostics launches test centers in 3 states

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LUCD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

LUCD Company Calendar

Last Earnings: 3/28/2022
Today: 8/18/2022
Next Earnings (Estimated): 11/22/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LUCD
CUSIP: N/A
CIK: 1799011
Web: www.luciddx.com
Phone: 212-949-4319
Fax: N/A
Employees: 2,021
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.54
High Stock Price Forecast: $21.00
Low Stock Price Forecast: $4.25
Forecasted Upside/Downside: +251.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,080,000.00
Net Margins: N/A
Pretax Margin: -6,553.85%
Return on Equity: -156.28%
Return on Assets: -104.34%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.55
Quick Ratio: 3.71

Sales & Book Value

Annual Sales: $500,000.00
Price / Sales: 227.58
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.96 per share
Price / Book: 3.13

Miscellaneous

Outstanding Shares: 37,930,000
Free Float: N/A
Market Cap: $113.79 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Lishan Aklog M.D. (Age 56)
Chairman & CEO
Mr. Dennis M. McGrath CPA (Age 65)
CFO, Pres & Sec.
Dr. Sanford D. Markowitz M.D.
Ph.D., Cofounder & Strategic Advisor, Member of the Medical Advisor Board
Dr. Joseph Willis M.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Dr. Amitabh Chak M.D.
Cofounder, Strategic Advisor & Member of Medical Advisory Board
Mr. Shaun M. O'Neill M.B.A. (Age 40)
Exec. VP & COO
Richard D. Yazbeck
Chief Technology Officer
Dr. Suman M. Verma M.D.
Ph.D., Chief Scientific Officer
Mr. Adrian K. Miller
VP of Investor Relations
Dr. Brian J. deGuzman M.D. (Age 57)
Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUCD Stock - Frequently Asked Questions

Should I buy or sell Lucid Diagnostics stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucid Diagnostics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUCD shares.
View LUCD analyst ratings or view top-rated stocks.
What is Lucid Diagnostics' stock price forecast for 2022?: 6 brokers have issued 12 month price targets for Lucid Diagnostics' stock. Their LUCD share price forecasts range from $4.25 to $21.00. On average, they predict the company's stock price to reach $10.54 in the next year. This suggests a possible upside of 246.8% from the stock's current price.
View analysts price targets for LUCD or view top-rated stocks among Wall Street analysts.
How have LUCD shares performed in 2022?: Lucid Diagnostics' stock was trading at $5.37 at the beginning of the year. Since then, LUCD shares have decreased by 43.4% and is now trading at $3.04.
View the best growth stocks for 2022 here.
When is Lucid Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 22nd 2022.
View our LUCD earnings forecast.
How were Lucid Diagnostics' earnings last quarter?: Lucid Diagnostics Inc. (NASDAQ:LUCD) issued its quarterly earnings data on Monday, March, 28th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.12.
When did Lucid Diagnostics IPO?: (LUCD) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share.

What is Lucid Diagnostics' stock symbol?: Lucid Diagnostics trades on the NASDAQ under the ticker symbol "LUCD."
Who are Lucid Diagnostics' major shareholders?: Lucid Diagnostics' stock is owned by a number of retail and institutional investors. Top institutional investors include Luminus Management LLC (2.30%), Nantahala Capital Management LLC (0.81%), Geneos Wealth Management Inc. (0.11%), Millennium Management LLC (0.06%), Bank of Montreal Can (0.04%) and LPL Financial LLC (0.04%).
How do I buy shares of Lucid Diagnostics?: Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Lucid Diagnostics' stock price today?: One share of LUCD stock can currently be purchased for approximately $3.04.
How much money does Lucid Diagnostics make?: Lucid Diagnostics (NASDAQ:LUCD) has a market capitalization of $115.31 million and generates $500,000.00 in revenue each year. The company earns $-28,080,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.
How many employees does Lucid Diagnostics have?: The company employs 2,021 workers across the globe.
How can I contact Lucid Diagnostics?: The official website for the company is www.luciddx.com. The company can be reached via phone at 212-949-4319 or via email at pavmed@lavoiehealthscience.com.

This page (NASDAQ:LUCD) was last updated on 8/18/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Lucid Diagnostics - LUCD Stock Forecast, Price & News

Lucid Diagnostics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month